The UK and US have hammered out a major bilateral deal that will ensure no duties on British pharmaceutical exports being sold in the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to boost expenditure on medicines through the public health system. This commitment ensures that tariffs on these key products will remain at zero for a period of 36 months.
This deal is in response to previous warnings to significantly raise import taxes on branded pharmaceutical imports, with potential rates floated reaching double the cost.
"This arrangement between the UK bolsters the worldwide climate for cutting-edge drugs and establishes much-needed fairness to transatlantic medicine commerce," a statement noted.
Trade Importance
Drugs constitute one of the Britain's most significant exports to the US, which is easily the biggest destination for major British pharmaceutical firms.
Export figures show that in the one-year period leading up to September, the UK sold pharmaceutical products valued at billions to the US. This figure represented nearly one-fifth of total UK exports in that period.
"This deal safeguards jobs, increases capital expenditure and paves the way for the UK to become a global hub for biotech and pharma," a government official commented.
Specific UK Commitments
The pact includes several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to double total public funding on medicines from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must refund to the NHS to stay within budget will be restricted at 15%. Last year, repayments topped 20%.
Recent Tensions
The pact follows a protracted row between the sector and the British authorities over drug pricing and regulatory access.
This friction were intensified by arguments that US patients were charged several times more for the identical medicines than patients in the Britain and the EU.
In recent months, several major drug company projects in the UK have been halted or cancelled, while major funding commitments have been pledged toward US facilities.
One official acknowledged that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the previous ten-year period.
